Ocular manifestations of patients with extranodal NK/T-cell lymphoma.
[AIMS] To investigate the ocular symptoms and characteristics exhibited by extranodal NK/T-cell lymphoma (ENKTL) patients.
- 표본수 (n) 4
APA
Luo J, Tao R, et al. (2025). Ocular manifestations of patients with extranodal NK/T-cell lymphoma.. Eye (London, England), 39(18), 3243-3248. https://doi.org/10.1038/s41433-025-04052-1
MLA
Luo J, et al.. "Ocular manifestations of patients with extranodal NK/T-cell lymphoma.." Eye (London, England), vol. 39, no. 18, 2025, pp. 3243-3248.
PMID
41057714
Abstract
[AIMS] To investigate the ocular symptoms and characteristics exhibited by extranodal NK/T-cell lymphoma (ENKTL) patients.
[METHODS] One hundred sixty-eight patients with mature T/Natural Killer-cell Lymphoma (MTNKL) were recruited in this study, among whom 107 cases were ENKTL patients. A retrospective analysis was conducted on 12 of these ENKTL patients who had ocular symptoms. Results of ophthalmic and systemic auxiliary examinations, disease progression, and prognosis were documented.
[RESULTS] Ocular symptoms occurred in bilateral eyes (n = 4) and unilateral eyes (n = 8). The average interval from the diagnosis of ENKTL to the onset of ocular symptoms was 18.1 (±20.8) months. According to the ocular symptoms and auxiliary examinations, eight patients had ocular adnexal symptoms only, and four patients had intraocular symptoms only. All patients exhibited impaired vision. After receiving combined treatment with systemic chemotherapy, radiotherapy, and local ocular therapy, six patients died during the follow-up, and the median survival time from diagnosis was 17 (range: 2-45) months. Among the surviving six patients, five out of seven eyes had poor visual prognoses lower than hand motion (HM), while two maintained a visual acuity of 20/25.
[CONCLUSION] In this study, the ocular presentations can be easily confounded with conditions such as uveitis or orbital cellulitis, necessitating vigilant clinical differentiation. To date, the visual prognoses of ENKTL patients with ocular symptoms remain regrettably poor.
[METHODS] One hundred sixty-eight patients with mature T/Natural Killer-cell Lymphoma (MTNKL) were recruited in this study, among whom 107 cases were ENKTL patients. A retrospective analysis was conducted on 12 of these ENKTL patients who had ocular symptoms. Results of ophthalmic and systemic auxiliary examinations, disease progression, and prognosis were documented.
[RESULTS] Ocular symptoms occurred in bilateral eyes (n = 4) and unilateral eyes (n = 8). The average interval from the diagnosis of ENKTL to the onset of ocular symptoms was 18.1 (±20.8) months. According to the ocular symptoms and auxiliary examinations, eight patients had ocular adnexal symptoms only, and four patients had intraocular symptoms only. All patients exhibited impaired vision. After receiving combined treatment with systemic chemotherapy, radiotherapy, and local ocular therapy, six patients died during the follow-up, and the median survival time from diagnosis was 17 (range: 2-45) months. Among the surviving six patients, five out of seven eyes had poor visual prognoses lower than hand motion (HM), while two maintained a visual acuity of 20/25.
[CONCLUSION] In this study, the ocular presentations can be easily confounded with conditions such as uveitis or orbital cellulitis, necessitating vigilant clinical differentiation. To date, the visual prognoses of ENKTL patients with ocular symptoms remain regrettably poor.
MeSH Terms
Humans; Female; Male; Lymphoma, Extranodal NK-T-Cell; Retrospective Studies; Middle Aged; Adult; Aged; Young Adult; Visual Acuity; Prognosis; Eye Neoplasms; Adolescent; Vision Disorders
같은 제1저자의 인용 많은 논문 (5)
- Adverse event reporting patterns associated with Degarelix and Relugolix: a pharmacovigilance study based on the FAERS database.
- Cardiotoxicity induced by traditional chemotherapy: mechanisms and mitigation strategies.
- Nuclear envelope rupture and DNA damage driven by high pressure are mediated by F-actin and induce hepatocyte inflammation via cGAS-STING.
- YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis.
- The Presentation Patterns of Tessier 7 Clefts.